(RTR) Mexico's Pemex says weighing Repsol ties after energy reform

Mexico's Pemex says weighing Repsol ties after energy reform {http://reut.rs/192au7p}


MADRID, Dec 19 (Reuters) - The long-time oil alliance between Mexico's Pemex and Spain's Repsol <REP.MC is reaching a crossroads as the Mexican state-run firm seeks to take advantage of a historic energy reform in its home country to expand its foreign presence, a director said.

The relationship between the two companies started to fray two years ago after a failed attempt to oust Repsol's chairman, Antonio Brufau, and reached a climax last month when Pemex , which holds a 9.4 percent stake in Repsol, voted against the Spanish firm's management.

But Arturo Henriquez, Pemex's representative on the board, said in an interview with Reuters that there was still time to repair the partnership and even take it forward by seizing jointly new opportunities in oil-rich Mexico and beyond.

Mexico voted last week to open its oil and gas sector to foreign investors for the first time in 75 years as part of a sweeping energy reform.

"The energy reform is a major milestone for Pemex," said Henriquez, who is also chairman and chief executive of Houston-based subsidiary Pemex Procurement International Inc. (PPI).

"We have to assess the investments we have on the table in light of such a dramatic game changer for the company. ... We want to evaluate whether Repsol is an ally for this new era. If so, excellent. We'll have to boost (the partnership) and if not, we'll have to take a decision."

He said the Mexican company has made a priority of seeking juicier returns from its 25-year investment in Repsol.

Pemex played an active role in striking a multi-billion-dollar deal to compensate Repsol for the nationalization of its former Argentine subsidiary YPF, although the boardroom drama that followed threatened last month to fracture further the strategic accord between the two.

While some analysts speculated Pemex could even sell its stake in the Spanish oil major, Henriquez said Repsol, with specialized deepwater technology, could be an ideal partner to explore Mexico's undeveloped resources given the long relationship and the cultural ties between the two companies.

Mexico has Latin America's third-largest proven crude reserves after Venezuela and Brazil with more than 10 billion barrels, and it also has nearly 30 billion barrels of prospective resources in its territorial deep waters of the Gulf of Mexico.

Henriquez stressed, however, that any partner would not only have to offer technology but also help the company expand in new markets. These could include the United States, Europe or Asia.

"What we want from any alliance, whether with Repsol, Exxon or Chevron is help in developing expertise, technology, capital ... mainly in deep water and shale oil and gas," he said.

Both Chevron and Exxon Mobil Corp have expressed broad support for Mexico's reforms, though final investment decisions will likely depend on how new rules are implemented.

Another potential partner could be Royal Dutch Shell , with which Pemex has a profitable 50-50 refinery tie-up in Texas, the sixth-largest in the United States.

"We're in a privileged position, in fashion as the latest country to open up its energy sector. Right now everyone wants to come to Mexico," said Henriquez. (Additional reporting by Reuters Breaking Views columnist Fiona Maharg Bravo in Madrid and David Alire Garcia in Mexico City; Editing by Julien Toyer and Leslie Adler)

>>> US Gapping down:

Gapping down:

In reaction to disappointing earnings/guidance: TIBX -11.15%, NAV -8.8%, SWFT -6.8%, KMX -5.3%, AVD -5.1%, BBRY -5.0%,

Other news: WPCS -24.12% (following earnings/acquisition conference call in after-hours), IDCC -10.94% (co lost a patent case against Nokia (NOK), Huaweui, and ZTE), DHT -5.4% (Filed for ~28.13 mln share common stock offering by selling shareholders), PSDV -6.8% (following yesterday's surge), BSPM -2.8% (filed for $35 mln mixed securities shelf offering), ALIM -2.2% (following yesterday's surge), ALU -0.88% (agrees to sell LGS Innovations LLC, its US Federal Government-serving subsidiary, to Madison Dearborn Partners and CoVant, for a total amount of up to $ 200 million),

>>> US Gapping up

Gapping up

In reaction to strong earnings/guidance: RHT +13.84%, FINL +4.63%, WAG +1.83%

M&A news: JNY +4.39%(To be acquired by Sycamore Partners for $15 per share in cash); GENT +2.4% (To be acquired by Jazz Pharmaceuticals for $57 per share in cash tender offer)

Other news: AMRN +15.09%( receives FDA notification that action on ANCHOR sNDA review will be delayed), APRI +7.4% (announced national phase approval for erectile dysfunction cream - Vitaros in France), TRAK +6.7% (announced agreement to acquire Dealer.com for 8.7 mln shares of common stock and $620 mln in cash), CIM +2.56% (Announced special dividend of $0.20 per share),BCRX +1.44% (files peramivir NDA for the treatment of influenza ), RAD +0.77% (along with WAG)

Analyst comments: CCL +3.68% (upgraded to Outperform from Neutral at Credit Suisse; raises tgt to $43), ARRS +0.78% (upgraded to Buy from Hold at Jefferies; tgt $30)

(BFW) Telefonica Deutschland, E-Plus Deal Gets In-Depth EU Probe

+------------------------------------------------------------------------------+

BN 12/20 12:30 Telefonica Deutschland, E-Plus Deal Gets In-Depth EU Probe

+------------------------------------------------------------------------------+

Telefonica Deutschland, E-Plus Deal Gets In-Depth EU Probe 2013-12-20 13:18:25.406 GMT

By Sam Chambers Dec. 20 (Bloomberg) -- Regulators had concerns that the transaction may reduce competition for retail mobile customers, lower wholesale access bought by MVNOs. * The EC has set a May 14 deadline to rule on the deal. Story * O2 Deutschland shrs -1.1%, KPN -0.4% * NOTE: Proposed merger is seen as pivotal for sector sentiment

For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>

--Editor: James Ludden

To contact the reporter on this story: Sam Chambers in London at +44-20-7673-2021 or schambers7@bloomberg.net

To contact the editor responsible for this story: James Ludden at +44-20-7673-2645 or jludden@bloomberg.net

>>> US Early Pre-Market Gappers

Early Pre-Market Gappers

Gapping up: AMRN +15.09%, RHT +13.84%, FINL +4.63%, JNY +4.39%, CUK +4.35%, WMC +3.64%, CCL +3.68%, SOL +3.13%, CIM +2.56%, HIMX +2.51%, WAG +1.83%, BCRX +1.44%, FE +1.42%, DRYS +1.34%

Gapping down: WPCS -24.12%, TIBX -11.15%, IDCC -10.94%, AA -2.71%, ORAN -2.35%, NBG -2.09%, DGI -1.34%, VALE -1.28%, ARMH -1.01%, QCOM -0.99%, ALU -0.88%

>>> Amarin Receives FDA Notification That Action on ANCHOR sNDA Review Will be D

Amarin Receives FDA Notification That Action on ANCHOR sNDA Review Will be Delayed; FDA Reviewing Amarin Request to Reinstate ANCHOR SPA
- Announced today that the U.S. Food and Drug Administration (FDA) notified the company last night that the FDA does not expect to take action on Amarin's supplemental new drug application (sNDA) for the proposed ANCHOR indication labeling expansion for Vascepa(icosapent ethyl) capsules on the December 20, 2013 Prescription Drug User Fee Act (PDUFA) goal date because Amarin's request to re-instate the ANCHOR Special Protocol Assessment (SPA) agreement remains under consideration with the FDA. No new PDUFA date was established.
- The FDA also communicated to Amarin that it now views Amarin's appeal of the ANCHOR SPA agreement rescission and the ANCHOR sNDA as separate administrative decisions worthy of separate consideration. FDA plans to complete its review of Amarin's request to re-instate the ANCHOR SPA agreement and plans to convey its decision to Amarin no later than January 15, 2014. The FDA provided no additional information on when it expects to complete its review of the ANCHOR sNDA.
- Vascepa is currently FDA approved for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe (=500 mg/dL) hypertriglyceridemia. The ANCHOR sNDA seeks approval of Vascepa for use as an adjunct to diet and exercise for adult patients on statin therapy with mixed dyslipidemia (one or more lipid disorder) and triglyceride levels between 200 and 499 mg/dL.
- Amarin plans to continue to work with the FDA to pursue reinstatement of the ANCHOR SPA agreement and approval of the ANCHOR sNDA. There can be no assurance that Amarin will be successful in this effort.